A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT02152371

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02152371
  • EudraCT 2012-004229-25
Other papers using this trial's data
  • Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9) Clinical therapeutics, 2017-11 DOI, PubMed 29110972

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Italy, Puerto Rico, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02152371. Randomized; double masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2016-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
Acronym
AWARD-9
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Metformin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02152371
Content hash
621023d9681c302bbb235b8268ac138fdafe97f5a93b223179461aaa74c16e51